GlassScriptPhysician profile
Samuel Bradberry
NPI 1588644397
$1,565.29
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $178 · 2021: $293 · 2022: $118 · 2023: $370 · 2024: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.68 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $158.74 | 2022-2024 | Repatha, Otezla |
| Abbvie INC. | $152.59 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $141.17 | 2019-2024 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $102.48 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $81.07 | 2020-2021 | |
| Pfizer INC. | $69.48 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.50 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $60.20 | 2019 | |
| Eisai INC. | $53.70 | 2020-2022 | |
| Axsome Therapeutics, INC. | $45.50 | 2023-2024 | Auvelity |
| Glaxosmithkline, LLC. | $34.66 | 2020 | |
| Merck Sharp & Dohme LLC | $34.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.01 | 2021 | |
| Esperion Therapeutics, INC. | $26.51 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.59 | 2024 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $22.77 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.96 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.40 | 2024 | Trulance, Xifaxan |
| Genentech USA, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Bradberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.